# The AdAPT Trial; Adenovirus After Allogeneic Pediatric Transplantation

> **NCT03339401** · PHASE2 · TERMINATED · sponsor: **Jazz Pharmaceuticals** · enrollment: 29 (actual)

## Conditions studied

- Adenovirus

## Interventions

- **OTHER:** Standard of Care
- **DRUG:** Brincidofovir

## Key facts

- **NCT ID:** NCT03339401
- **Lead sponsor:** Jazz Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-12-22
- **Primary completion:** 2019-05-10
- **Final completion:** 2019-05-10
- **Target enrollment:** 29 (ACTUAL)
- **Why stopped:** terminated due to low enrollment rate
- **Last updated:** 2021-01-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03339401

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03339401, "The AdAPT Trial; Adenovirus After Allogeneic Pediatric Transplantation". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03339401. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*